Laura Joszt, MA

The approval is the first in more than a decade for an idiopathic pulmonary fibrosis treatment.

Stephen Greene, MD, discusses the future and practical implications of optimizing quadruple foundational therapies for patients with heart failure.

Research highlights disparities in anti-obesity medication use and metabolic and bariatric surgery.

Colon cancer recurrence risk falls below 0.5% at 6 years post-surgery, offering a practical benchmark for defining cure, according to new research.

Lurbinectedin has been approved to be used in combination with atezolizumab or atezolizumab and hyaluronidase.

Amivantamab plus lazertinib enhances survival in NSCLC but requires complex care compared with osimertinib, explained Danny Nguyen, MD, of City of Hope.

The Trump administration advances the Most Favored Nation order by partnering with Pfizer, which came to the table voluntarily and has been granted a reprieve from upcoming drug tariffs.

Oncology pharmacists now work alongside providers to improve efficiency, patient education, and treatment outcomes, according to Scott Soefje, PharmD, MBA, BCOP.

Oncology care requires teamwork, support services, and careful planning to ensure effective, affordable, and patient-focused treatment, according to Brian Mulherin, MD.

Clinician's role in breast cancer care and access with reproductive and urinary oncologist Lakshminarayanan Nandagopal, MD

Hope Krebill of the Masonic Cancer Alliance at the University of Kansas Medical Center outlines patient navigation models that improve outcomes and reduce missed appointments.

Cardiopulmonary risk is high and persistent across the entire COPD disease course, making early recognition and integrated care crucial.

Research reveals strong connections between muscle strength and cognitive function in patients with COPD, highlighting the potential for rehabilitation strategies.

Advancements in breast cancer care and treatments with reproductive and urinary oncologist Lakshminarayanan Nandagopal, MD.

Nerandomilast for idiopathic pulmonary fibrosis potentially improves survival and slows disease progression, explains Justin Oldham, MD, PhD, MS, FIBRONEER steering committee member.

There are clear benefits to starting biologic therapy earlier for severe asthma, as well as initiation patterns by ethnicity, according to data at ERS Congress 2025.

In a time of skyrocketing oncology drug costs, the role of pharmacists in managing patients’ treatment and keeping care in the outpatient setting is more urgent than ever.

Patients with hematologic malignancies face ongoing survivorship challenges as providers struggle to coordinate care, according to Brian Koffman, MDCM, DCFP, FCFP, DABFP, MSEd.

The evolving treatment landscape for unfit patients with newly diagnosed acute myeloid leukemia (AML) centers on venetoclax combination and personalized strategies.

FDA approved the monotherapy for estrogen receptor (ER)–positive and HER2-negative metastatic breast cancer.

Oncology utilization management often frustrates patients and payers, but collaboration and artificial intelligence can streamline processes and improve care quality, according to Vishnukamal Golla, MD, MPH.

As therapeutic advances enable patients with cancer to live longer, greater attention is needed to support the goal of survivorship, starting at diagnosis.

Researchers found that even smaller open artificial intelligence (AI) models outperformed clinicians, supporting automation of International Classification of Disease (ICD) coding.

Stacy Knox, PharmD, BCPS, BCACP, DPLA, discusses how centralized pharmacy teams and electronic health record integration streamline prior authorizations, enhance provider efficiency, and offer patients transparent, real-time updates.

High discontinuation rates of semaglutide among older adults with diabetes reveal challenges in long-term adherence and highlight the need for improved support strategies.

Leucovorin is under FDA review to expand treatment for children with cerebral folate deficiency, which has been assciated with autism.

Patients with acute myeloid leukemia (AML) in remission for over 3 years experience survival rates comparable with a matched cohort from the general population.

Ruxolitinib cream received an expanded approval to treat patients as young as 2 years old with non-immunocompromised mild to severe atopic dermatitis.

The governors California, Oregon, Washington, and Hawaii came together to announce their winter virus recommendations.